PATENT CLAIM ANALYSIS

Application Number: 15956909
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["424", "009200"]

Abstract:
Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4 +  T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.

Claim (Index 4):
A pharmaceutical composition comprising chemokine CCL3 and an immunogen selected from the group consisting of a tumor-associated, a tumor-specific antigen, an antigen of an infectious agent, a dendritic cell vaccine, an antigen-pulsed dendritic cell vaccine, and dendritic cells pulsed with a CMV integument protein pp65 RNA.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 91.0
- Lexical Diversity: 1.5
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15036878', '11718391', '13825078', '11773162', '15024200']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6802601277968223
- 35 USC 102 Novelty (BERT): 0.6707595822666864
- Combined Prediction Score: 0.6793100732438088
- Mean Citation Score: 406.404084
- Max Citation Score: 841.20935
- Similarity Product: 625.9845696628272

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test